KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial.

P Filis, X Liu, A Matikas, M Untch, G G Steger, H Johansson, M Hellström, M Gnant, S Loibl, Y Brandberg, J Bergh, T Foukakis

ESMO Open 11(5) 107696

PMID42215159
PMCIDPMC13242076
DOI10.1016/j.esmoop.2026.107696
发表日期2026-05-29
入排依据:The study is a secondary analysis of patient-reported outcomes and clinician-reported toxicities from a randomized phase III trial. While it is an oncology trial in humans with a drug intervention, the primary and key secondary endpoints are not time-to-event efficacy measures (e.g., OS, PFS, DFS). The analysis focuses on concordance between clinician- and patient-reported symptoms, not survival or progression endpoints.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:生活质量量表图;Figure 2:生活质量量表图。
摘要

摘要

BACKGROUND: Although advances in systemic therapy have markedly improved survival in breast cancer, treatment-related toxicities remain a major determinant of health-related quality of life (HRQoL). Clinician reports may not fully capture the symptom burden experienced by patients. This study examined the concordance between clinician-reported toxicities and patient-reported symptom scores during adjuvant chemotherapy for early-stage, high-risk breast cancer in a randomized phase III clinical trial. PATIENTS AND METHODS: Clinician-reported toxicities were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and patient-reported symptom scores were obtained with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC QLQ-BR23 questionnaires at mid- and end-of-treatment. Analyses focused on six symptomatic domains with conceptual overlap between CTCAE and EORTC measures: diarrhea, nausea, vomiting, mucositis, pain, and fatigue. Concordance between clinician- and patient-reported scores was evaluated using weighted Cohen's kappa coefficients. RESULTS: A total of 1566 patients with available CTCAE and HRQoL data were included in the analysis. Agreement between clinician-reported toxicities and patient-reported symptom scores was low across all symptoms and time points, with kappa values indicating no to minimal concordance (kappa = 0.07-0.34). Clinician-assigned CTCAE grades were predominantly lower than patient-reported symptom severity. The highest discrepancy rates were observed for fatigue (36%-54%) and pain (23%-38%) across treatment arms and time points. Except for nausea and vomiting, the magnitude of the discrepancy increased from mid- to end-of-treatment in both study arms. Binary analyses comparing the presence of any versus no symptom confirmed persistently low agreement between clinicians and patients (kappa = 0.03-0.35). CONCLUSION: Clinician-reported toxicities showed poor concordance with patient-reported symptom severity, and the discrepancy increased over time. Incorporating patient-reported assessments into both clinical trials and routine care is essential to ensure more accurate evaluation of treatment tolerability.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Discordance between clinician-assigned toxicity grading and patient-reported symptoms. Heatmap of the proportion of cases in which clinician-assigned CTCAE grades were lower than patient-reported EORTC symptom scores, stratified by treatment arm and timepoint (middle versus end of treatment). Each cell shows the percentage of underreporting for the corresponding symptom, with lighter shades of red indicating lower rates and darker shades indicating higher rates (observed range: 4.6%-70.8%). The figure highlights that discordance was most pronounced for mucositis, fatigue, and pain. CTCAE, Common Terminology Criteria for Adverse Events; EORTC, European Organisation for Research and Treatment of Cancer.
非 KM Figure
Figure 2Change in discordance between clinician-assigned toxicity and patient-reported symptom severity from mid- to end-of-treatment. Bars show the percentage point change in discordance rates (clinician-reported CTCAE grade lower than the corresponding EORTC symptom score) between mid- and end-of-treatment, stratified by treatment arm. Positive values indicate an increase in underreporting from the middle to end of treatment, whereas negative values indicate a decrease. Asterisks denote statistical significance from McNemar’s test ( P < 0.05), based on paired patients with available data at both time points. CTCAE, Common Terminology Criteria for Adverse Events; EORTC, European Organisation for Research and Treatment of Cancer.
非 KM Figure